Pfizer
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.
Business & Industry
- Bristol-Myers Squibb provides update on pending merger with Celgene
- Regorafenib to be tested in brain cancer patients in multi-arm cooperation trial
- Breztri Aerosphere (PT010) approved in Japan for patients with chronic obstructive pulmonary disease
- Japan becomes the first country to approve Roche's personalised medicine Rozlytrek
- FDA approves Amgen and Allergan's KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab)
Research & Development
- Pathogen engineered to self-destruct underlies cancer vaccine platform
- Human-on-a-chip model tests cancer drug efficacy and toxicity for therapeutic index
- Vitamin D may not help your heart
- Researchers identify enzyme that suppresses immune system in breast cancer
- Making it personal: How genetic technologies are changing the face of medicine
- Weighing risks and benefits of drug treatment for major depression
- Study finds FDA dermatology advisors receive payments following drug approvals
Conferences & Events
- The need for a blueprint emergency plan to avoid a HPAPI crisis
- Ophthalmic Drugs Conference 2019
- Lyophilization USA Conference 2019
- Highly Potent Active Pharmaceutical Ingredients USA (HPAPI) Conference
- Wearable Injectors and Connected Devices Conference 2019
- Researchers block protein that plays a key role in Alzheimer's disease
- Highly Potent APIs 2019 Conference
Regulatory Affairs
- FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma
- FDA announces Project Facilitate to assist physicians seeking access to unapproved therapies for patients with cancer
- FDA approves first anticoagulant (blood thinner) for pediatric patients to treat potentially life-threatening blood clots
- FDA approves first treatment for children with Lambert-Eaton myasthenic syndrome
- FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis